InspireMD (NSPR) Set to Announce Quarterly Earnings on Wednesday

InspireMD (NYSE:NSPRGet Free Report) is scheduled to be posting its 12/31/2023 quarterly earnings results before the market opens on Wednesday, March 6th. Analysts expect InspireMD to post earnings of ($0.20) per share for the quarter.

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $2.56 on Tuesday. The company’s fifty day moving average is $2.79 and its two-hundred day moving average is $2.96. The stock has a market capitalization of $55.17 million, a price-to-earnings ratio of -1.68 and a beta of 0.84. InspireMD has a 1-year low of $0.96 and a 1-year high of $3.85.

Hedge Funds Weigh In On InspireMD

A number of institutional investors and hedge funds have recently bought and sold shares of NSPR. Renaissance Technologies LLC bought a new position in shares of InspireMD during the 2nd quarter valued at about $36,000. Northern Trust Corp bought a new position in shares of InspireMD during the 4th quarter valued at about $80,000. Nantahala Capital Management LLC boosted its position in shares of InspireMD by 16.9% during the 4th quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock valued at $5,807,000 after purchasing an additional 298,406 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of InspireMD during the 2nd quarter valued at about $4,670,000. Institutional investors own 1.34% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of InspireMD in a research report on Wednesday, February 28th. They set a “sell” rating for the company.

Check Out Our Latest Report on InspireMD

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.

Featured Articles

Earnings History for InspireMD (NYSE:NSPR)

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.